TScan Therapeutics, Inc. (TCRX) Posts Fourth Quarter Loss, Falls Short of Revenue Expectations

TScan Therapeutics, Inc. (TCRX) Reports Quarterly Results

TScan Therapeutics, Inc. (TCRX) announced a quarterly loss of $0.18 per share, which was better than the anticipated loss of $0.27 per share according to Zacks Consensus Estimate. In comparison, the company reported a loss of $0.29 per share in the same period last year. These results exclude one-time items.

This quarter's performance resulted in a positive earnings surprise of 34.31%. In the previous quarter, the company was projected to lose $0.35 per share but actually reported a smaller loss of $0.28, marking a 20% surprise. Over the past four quarters, TScan has exceeded consensus earnings per share estimates three times.

Operating within the Medical - Biomedical and Genetics sector tracked by Zacks, TScan Therapeutics generated $2.57 million in revenue for the quarter ending December 2025, which fell short of the consensus estimate by 37.08%. This is a significant increase from the $0.67 million reported a year earlier. The company has surpassed revenue expectations twice in the last four quarters.

The immediate movement of TScan’s stock price, as well as its future trajectory, will largely hinge on management’s insights shared during the earnings call.

Since the start of the year, TScan Therapeutics shares have risen approximately 3.5%, while the S&P 500 has declined by 0.4% over the same period.

Looking Ahead: What’s Next for TScan Therapeutics?

Although TScan Therapeutics has outperformed the broader market so far this year, investors are now wondering about the company’s future prospects.

One key indicator for investors is the company’s earnings outlook, which includes both current consensus estimates for upcoming quarters and any recent changes to those projections.

Research indicates that short-term stock price movements are closely linked to trends in earnings estimate revisions. Investors can monitor these changes themselves or use established tools like the Zacks Rank, which has a strong record of leveraging earnings estimate trends.

Prior to this earnings announcement, TScan’s estimate revision trend was mixed. While the latest results may influence future revisions, the current outlook gives TScan a Zacks Rank #3 (Hold), suggesting the stock is likely to perform in line with the market in the near term.

It remains to be seen how analyst estimates for the next quarters and the current fiscal year will evolve. At present, the consensus is for an EPS of -$0.18 on $2.5 million in revenue for the next quarter, and -$0.99 on $9.42 million in revenue for the full year.

Investors should also consider the broader industry outlook, as it can significantly affect individual stock performance. The Medical - Biomedical and Genetics industry currently ranks in the bottom 44% of over 250 Zacks-tracked industries. Historically, the top half of Zacks-ranked industries outperforms the bottom half by more than two to one.

Industry Comparison: Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals (LXRX), another company in the same sector, has not yet released its results for the quarter ending December 2025. The report is expected on March 5.

Analysts predict Lexicon will post a quarterly loss of $0.07 per share, reflecting a 22.2% improvement from the previous year. The consensus EPS estimate has remained steady over the past month.

Revenue for Lexicon Pharmaceuticals is projected at $4.42 million, which would be an 83.4% decrease compared to the same quarter last year.

Is TScan Therapeutics, Inc. (TCRX) a Good Investment?

Thinking about investing in TScan Therapeutics, Inc. (TCRX)?

Since 1978, Zacks Investment Research has provided independent analysis and tools for investors. Over the past 25+ years, the Zacks Rank stock-rating system has delivered an average annual return of 24.08%, more than doubling the S&P 500’s performance from January 1, 1988, through May 6, 2024.